90% OF DUODENAL ULCER PATIENTS HAVE CAMPYLOBACTER PYLORI!



This bacterium is commonly found in the gastric antrum of patients with peptic ulcer.

Epidemiological studies show its presence in around 70% of gastric ulcer patients and in upwards of 90% of duodenal ulcer patients.

Campylobacter pylori is difficult to eradicate but there is one ulcer healing agent which can do this: De-Nol.

Patients whose duodenal ulcers have been healed with De-Nol and in whom Campylobacter pylori has been eradicated are likely to enjoy prolonged remission so

DE-NOL®

tri-potassium di-citrato bismuthate

STOPS ULCERS BUGGING YOU

℞ De-Noltab 2 b.d.

PRESENTATION: Each tablet or 5 ml dose contains 120 mg tri-potassium di-citrato bismuthate (calculated as Bi_2O_3). **USES:** Ulcer healing agent. For the treatment of gastric and duodenal ulcers. **DOSAGE AND ADMINISTRATION:** By oral administration. **Adults:** The more convenient dosage is two tablets or two 5 ml spoonsful twice daily (half an hour before breakfast and half an hour before the evening meal) for 28 days. Alternatively one tablet or one 5 ml spoonful four times a day (half an hour before each of the three main meals of the day and two hours after the evening meal) for 28 days. If necessary a further month's treatment may be given. Maintenance therapy with De-Nol is not indicated, but treatment may be repeated after an interval of one month. The tablets are to be taken with a draught of water and each 5 ml or 10 ml dose of the liquid diluted with 15 ml of water. **Children:** Not recommended. **CONTRA-INDICATIONS, WARNINGS, ETC:** De-Nol/De-Noltab should not be administered to patients with renal disorders and, on theoretical grounds, is contra-indicated in pregnancy. **Special precautions:** De-Nol/De-Noltab may inhibit the efficacy of orally administered tetracyclines. **Side effects:** Blackening of the stool usually occurs; nausea and vomiting have been reported. Darkening of the tongue may occur with De-Nol liquid only. **Overdosage:** Overdosage has rarely been reported; gastric lavage with intestinal evacuation and, if necessary, supportive therapy would be indicated. **PACKAGE QUANTITIES:** De-Noltab: Treatment pack of 112 tablets. De-Nol: Treatment pack of 560 ml. **LEGAL CATEGORY UK:** P. **BASIC N.H.S. PRICE:** De-Noltab: £20.98. De-Nol: £14.65. **PRODUCT LICENCE NUMBERS:** De-Noltab: 0166/0124. De-Nol: 0166/5024. **LEGAL CATEGORY REPUBLIC OF IRELAND:** To be supplied on prescription only. **G.M.S. PRICES:** De-Noltab: IR£26.65. De-Nol: IR£16.37. **PRODUCT AUTHORISATION NUMBERS:** De-Noltab: 62/22/2. De-Nol: 62/23/1.

REFERENCES: 1. Coghlan J G et al, Lancet 1987; 2:1109–1111. **2.** Smith A C et al, Gut 1988; 29:A711. **3.** Marshall B J et al, Lancet 1988; 2:1437–1442.
There are now so many publications on Campylobacter pylori and De-Nol that Brocades have compiled a 570 page bibliography on Campylobacter pylori and a 340 page bibliography on De-Nol. If you would like to receive copies of these please write to:

Gist-brocades

Brocades/GB/Limited, Brocades House, West Byfleet, Surrey KT14 6RA

BGB 4004/89

CAMPYLOBACTER PYLORI INFORMATION ADVERTISEMENT NO.2

FAST W

Thomas Morson Pharmaceuticals
Hertford Road, Hoddesdon, Hertfordshire
Division of Merck Sharp & Dohme Limited

ABRIDGED PRODUCT INFORMATION ▼
Refer to Data Sheet before prescribing.
INDICATIONS Duodenal ulcer; prevention of relapses of duodenal ulceration; benign gastric ulcer; hypersecretory conditions such as Zollinger-Ellison syndrome.
DOSAGE In duodenal and benign gastric ulcer, 40 mg at night for four to eight weeks. For prevention of duodenal ulcer recurrence, 20 mg at night. Initiate antisecretory therapy of Zollinger-Ellison syndrome with 20 mg every six hours and adjust to individual response. The maximum dosage used for up to one year was 480 mg daily.
CONTRA-INDICATION Hypersensitivity.

ORKER



'Pepcid' PM,
working fast to relieve
the pain of ulcers,[1] quickly
restoring the well-being
of many patients.
This rapid relief, together
with fast, effective healing,[2]
is achieved in many patients
with a simple dosage of
just one small 40 mg
tablet at night.

PEPCID® PM 40
(famotidine) ***mg***

ONE AT NIGHT CAN MAKE THEIR DAY

SPECIFICALLY DEVELOPED
FOR THE SUPPRESSION OF
NOCTURNAL ACID

PRECAUTIONS Exclude any likelihood of gastric carcinoma before using 'Pepcid' PM. Consider reducing the daily dose if creatinine clearance falls to or below 30 ml/min. 'Pepcid' PM is not recommended in pregnancy, nursing mothers or children.
SIDE EFFECTS Rarely, headache, dizziness, constipation, diarrhoea. Less frequently, dry mouth, nausea, vomiting, rash, abdominal discomfort, anorexia, fatigue.
BASIC NHS COST 20 mg tablets, £14.00 for 28-day calendar pack and £25.00 for bottles of 50. 40 mg tablets, £26.00 for 28-day calendar pack and £47.50 for bottles of 50.
Product Licence Numbers: 20 mg tablets, 0025/0215; 40 mg tablets 0025/0216. Issued December 1988.

▼Special reporting to the CSM required.
® denotes registered trademark of Merck & Co., Inc., Rahway, NJ, USA.

References

1. Rohner, H-G., and Gugler, R., *Amer. J. Med.*, 1986, *81* (Suppl. 4B), 13. 2. Dobrilla, G., *et al.*, *Scand. J. Gastroenterol.*, 1987, *22* (Suppl. 34), 21.

09-89 PCD.88.GB.3394.J

IT MAKES LIFE WORTH LIVING.

Effective control of ulcerative colitis is only half of Colifoam's success story. As thousands of patients previously managed with aqueous enemas have found, its simplicity and ease of retention has transformed their lives.

Colifoam causes little if any disturbance to their daily routine, and enables patients to enjoy their normal social and outdoor activities.[1]

Equally as effective as steroid enemas,[1,2] Colifoam is now established as the leading treatment for ulcerative colitis.[3] It is also unique among foam treatments with an unrivalled 12 years of proven efficacy and safety in clinical practice.

COLIFOAM
10% Hydrocortisone acetate foam.

The proven choice in ulcerative colitis.

PRESCRIBING INFORMATION: Presentation: White odourless aerosol containing hydrocortisone acetate PhEur 10%. Uses: Ulcerative colitis, proctosigmoiditis and granular proctitis. Dosage and administration: One applicatorful inserted into the rectum once or twice daily for two or three weeks and every second day thereafter. Shake can vigorously before use (illustrated instructions are enclosed with pack). Contra-indications, warnings etc.: Local contra-indications to the use of intrarectal steroids include obstruction, abscess, perforation, peritonitis, fresh intestinal anastomoses and extensive fistulae. General precautions common to all corticosteroid therapy should be observed during treatment with Colifoam. Treatment should be administered with caution in patients with severe ulcerative disease because of their predisposition to perforation of the bowel wall. Safety during pregnancy has not been fully established. Pharmaceutical precautions: Pressurized container. Protect from sunlight and do not expose to temperatures above 50°C. Do not pierce or burn even after use. Do not refrigerate. Keep out of reach of children. For external use only. Legal category: POM. Package Quantity & Basic NHS cost: 25g canister plus applicator, £7.25. Further Information: One applicatorful of Colifoam provides a dose of approximately 125mg of hydrocortisone acetate, similar to that used in a retention enema, for the treatment of ulcerative colitis, sigmoiditis and proctitis. Product Licence No.: 0036/0021. References 1. Somerville KW et al. British Medical Journal 1985; 291:866. 2. Ruddell WSJ et al. Gut 1980; 21:885-889. 3. Independent Research Audit. Data on File. Further information is available on request. Stafford-Miller Ltd., Professional Relations Division, Hatfield, Herts. AL10 0NZ.



Prescribing Information

▼ Abbreviated Prescribing Information Presentation: Capsules containing 150mg or 300mg nizatidine INN. **Uses:** For the treatment of duodenal and benign gastric ulcer, and prevention of duodenal ulcer recurrence. **Dosage and Administration:** (For full information, see data sheet). Axid is administered orally. *Adults:* For duodenal and benign gastric ulcer, the recommended daily dose is 300mg in the evening for 4 or, if necessary, 8 weeks. For prevention of duodenal ulcer recurrence, the recommended daily dose is 150mg in the evening. *The elderly:* Normally dosage modification is not required except in patients who have moderate to severe renal impairment. *Children:* Not recommended. *Patients with impaired renal function:* Moderate renal impairment (creatinine clearance less than 50ml/min), the dose should be reduced by 50% to 150mg in the evening. Severe renal impairment (creatinine clearance less than 20ml/min), the dose should be reduced by 75%, to 150mg on alternate days. Prevention of duodenal ulcer recurrence in moderate renal impairment (creatinine clearance less than 50ml/min), the dose may be reduced to 150mg on alternate days. Severe renal impairment (creatinine clearance less than 20ml/min), the dose may be reduced to 150mg every third day. **Contra-indication:** Known hypersensitivity to H_2-receptor antagonists. **Warnings:** *Usage in pregnancy:* The safety of nizatidine for use during pregnancy has not been established. *Usage in lactation:* Administer to nursing mothers only if considered absolutely necessary. *Drug Interactions:* No interaction has been observed between nizatidine and aminophylline, theophylline, chlordiazepoxide, diazepam, metoprolol, warfarin or lorazepam. Nizatidine does not inhibit the hepatic cytochrome P450-linked drug metabolising enzyme system. **Precautions:** Patients with impaired liver or kidney function should be treated with caution (see data sheet). **Side-effects:** Possible side-effects include sweating. In clinical trials, the following events were observed with a higher, but not significantly different, incidence than placebo: headache, asthenia, chest pain, myalgia, abnormal dreams, somnolence, rhinitis, pharyngitis, cough, pruritis, sweating and reversible, asymptomatic elevations of transaminases. *Overdosage:* There is no experience of overdose in humans. Tested at very high doses in animals, nizatidine has been shown to be relatively non-toxic. *Treatment:* Symptomatic and supportive therapy is recommended. Activated charcoal may reduce nizatidine absorption and haemodialysis may remove absorbed nizatidine. **Legal Category:** POM. **Product Licence Numbers:** Capsules 150mg 0006/0230. Capsules 300mg 0006/0231. **Basic NHS Cost:** Per 28-day calendar pack – 150mg capsules £13.44; 300mg capsules £25.76. **Date of Preparation:** June 1988. **▼** Special reporting to the CSM required. Advertising information is available from: Eli Lilly and Company Limited, Dextra Court, Chapel Hill, Basingstoke, Hants RG21 2SY. Telephone: 0256 841. 'AXID' is a Lilly trade mark.

1. Simon B, *et al. Scand J Gastroenterol* 1987; 22 (Suppl. 136): 61. 2. Naccaratto R, *et al. Scand J Gastroenterol* 1987; 22 (Suppl. 136): 71. [illegible] HG, *et al.* Topics in Peptic Ulcer [illegible] McColl KEL, European Nizatidine [illegible] Brussels Nov. 1987. 5. Hindmarch I, [illegible] Symposium, Brussels Nov. [illegible] M, *Scand J Gastroenterol* 1987;

Lilly

Axid 300mg

More than just an overnight success in H_2 therapy

Axid suppresses acid through the night to provide unsurpassed efficacy in ulcer healing and relief of symptoms.[1,2] But that's only half the story. During the day Axid allows a return to virtually normal gastric physiology.[3]

Daytime acid is important for the sterilisation of food and to help protein digestion and the absorption of iron and calcium. Unlike some other H_2 antagonists Axid has minimal effect on daytime acid secretion.[3]

Axid offers successful pain relief and ulcer healing without disrupting daytime gastric physiology.[1,2,4,5,6] This is in keeping with the current thinking among leading gastroenterologists, and is a reason why Axid is not just an overnight success story.

AXID 1 NOCTE 300 mg

NIZATIDINE

All the H_2 antagonism your patient needs

XX 129 Sept 88

WHY PICK THIS ONE?

All H$_2$ antagonists achieve effective duodenal ulcer healing... so why consider 'Tagamet' 800?

Cost:

the others are up to 60% more expensive*

Experience:

'Tagamet' has been prescribed more than twice as many times as all the others put together†

TAGAMET
CIMETIDINE 800

Just as peas in a pod are similar but not identical so too are the H$_2$ antagonists. Although structurally different and with some differing properties, they act via the same mechanism to achieve effective duodenal ulcer healing.
***The price comparison is based on manufacturers' recommended 4-week duodenal ulcer healing course using a one tablet nocte regimen. Prices are taken from MIMS September 1988 and represent the cost of 28 days' treatment. 'Tagamet' 800 mg £16.58, famotidine 40 mg £26.60, nizatidine 300 mg £25.76, ranitidine 300 mg £25.60.**
†Based on SK&F estimates of H$_2$RA prescriptions in the UK from November 1976 to July 1988.
Prescribing Information. Presentations 'Tagamet Tiltab' Tablets, each containing 800 mg cimetidine (PL 0002/0128: 30, 2 calendar strips of 15 tablets, £17.76). 'Tagamet' Tablets, each containing 400 mg cimetidine (PL 0002/0092: 60, 4 calendar strips of 15 tablets, £18.69). 'Tagamet' Syrup, PL 0002/0073, containing 200 mg cimetidine per 5 ml. 600 ml, £23.04. **Indication** Duodenal ulcer. **Dosage** *For full dosage instructions see Data Sheet. Adults.* 800 mg once a day at bedtime, or 400 mg b.d. with breakfast and at bedtime. Treat for at least 4 weeks. To prevent relapse, 400 mg at bedtime or 400 mg morning and at bedtime. *Children:* Over 1 year: 25-30 mg/kg/day, divided. **Cautions** Impaired renal function: reduce dosage (see Data Sheet). Potentiation of oral anticoagulants, phenytoin and theophylline (see Data Sheet). Prolonged treatment: observe patients periodically. Potential delay in diagnosis of gastric cancer (see Data Sheet). Care in patients with compromised bone marrow (see Data Sheet). Avoid during pregnancy and lactation. **Adverse reactions** Diarrhoea, dizziness, rash, tiredness. Gynaecomastia, occasional reversible liver damage, confusional states (usually in the elderly or very ill). Very rarely interstitial nephritis, acute pancreatitis, thrombocytopenia, headache, myalgia, arthralgia; very rare reports of alopecia, reversible impotence but no causal relationship established at usual therapeutic doses. **Legal category** POM. 10.6.88.
Smith Kline & French Laboratories Limited
A SMITHKLINE BECKMAN COMPANY
Welwyn Garden City, Hertfordshire AL7 1EY

SK&F
TG:AD1608

SUCH A REVOLUTIONARY NEW TREATMENT DESERVES FAR MORE THAN THE USUAL SMALL PRINT

Indications

Cytotec is indicated for the healing of duodenal ulcer and gastric ulcer including those induced by nonsteroidal anti-inflammatory drugs (NSAID) in arthritic patients at risk, whilst continuing their NSAID therapy. In addition Cytotec can be used for the prophylaxis of NSAID-induced ulcers.

Actions

Cytotec is an analogue of naturally occurring prostaglandin E_1 which promotes peptic ulcer healing and symptomatic relief.

Cytotec protects the gastroduodenal mucosa both by inhibiting basal, stimulated and nocturnal acid secretion and by reducing the volume of gastric secretions, the proteolytic activity of the gastric fluid, and increasing bicarbonate and mucus secretion.

For abbreviated prescribing information see overleaf

CYTOTEC®

GIVES 'AT RISK' ARTHRITIC PATIENTS THE PROTECTION TO STOMACH NSAIDs



CO·PRESCRIBE

CYTOTEC®

misoprostol

THE ONLY ANTI-ULCER AGENT LICENSED FOR CO-PRESCRIPTION WITH NSAIDs

CYTOTEC ▼ Abbreviated Prescribing Information
Presentation: Tablet containing misoprostol 200 micrograms. **Uses:** Healing of duodenal and gastric ulcer induced by nonsteroidal anti-inflammatory drugs (NSAID) in arthritic patients at risk, whilst continuing NSAID therapy. Prophylaxis of NSAID-induced ulcers. Healing of duodenal and gastric ulcer. **Dosage: Adults including the elderly. Healing of duodenal and gastric ulcer:** 800 micrograms daily in two or four divided doses taken with breakfast and/or each main meal and at bedtime. **Prophylaxis of NSAID-induced ulcer:** 200 micrograms twice daily, three times daily or four times daily. Refer to data sheet for additional information. **Contraindications:** Pregnant women, women of childbearing age, patients allergic to prostaglandins. **Precautions:** Cytotec does not produce hypotension in clinical studies at ulcer-healing doses, nevertheless exercise caution in disease states where hypotension might precipitate severe complications. **Adverse reactions:** Mild and transient diarrhoea may occur. Other adverse events reported included abdominal pain, dyspepsia, flatulence and nausea, although a causal relationship to Cytotec has not been established. **Basic NHS Price:** £26.00 per 112 pack. **Product Licence Number:** 0020/0115.

SEARLE
GOLD CROSS

G. D. Searle & Co. Ltd., P.O. Box 53, Lane End Road, High Wycombe, Bucks. HP12 4HL.
Cytotec, Searle and Gold Cross are registered trade marks. Data Sheet with full prescribing information is available on request.

FOR FURTHER INFORMATION
DIAL 100 AND ASK FOR

FREEFONE CYTOTEC

CY: JC108

PROGRESS

In The Control Of Pancreatic Insufficiency



creon®

pancreatin

RIGHT ON TARGET – RIGHT FROM THE START

Prescribing Information – Presentation: Brown-yellow capsules containing enteric coated granules of pancreatin equivalent to: 9,000 BP units of amylase, 8,000 BP units of lipase, 210 BP units of protease. Available in packs of 100. Basic NHS price £13.33. **Indication:** Pancreatic exocrine insufficiency. **Dosage and administration:** Adults and children: Initially one or two capsules with meals, then adjust according to response. The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food, it is important that they are taken immediately, otherwise dissolution of the enteric coating may result. **Contra-indications, Warnings, etc:** Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with high doses of pancreatin. Overdosage could precipitate meconium ileus equivalent. Perianal irritation could occur, and, rarely, inflammation when large doses are used. **Product Licence Number:** 5727/0001. **Name and address of Licence Holder:** Kali Chemie Pharma GmbH, Postfach 220, D-3000, Hannover 1, West Germany.

duphar Further information is available from: Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: 0703 472281.

CRAd/PEI/1/89

MIC AG, CH-4502 Solothurn, POB 706, Hauptgasse 29, Fernschreiber 34
Telefon 41-65-23 43 55-56, Telex 931 486 mic ch
Original Size

T

T

T

T



Pat. prot.

Gastrograph Mark II

Endoscopy without accessories is like surgery without scalpels

As fibreoptic and electronic endoscopes continue to develop, the demand grows for a wider range of accessories.
KeyMed has prepared a series of information bulletins on new Olympus accessories available now. Further bulletins will be published as other new accessories become available. To ensure you receive your copies as they are published, complete and return the freepost card.



Statement of facts

"Olympus is committed to the development of a comprehensive range of accessory products to improve diagnosis and further increase the therapeutic procedures that can be performed through a fiberscope."

KeyMed House, Stock Road, Southend-on-Sea, Essex SS2 5QH.
Telex: 995283, Facsimile: (0702) 65677, Telephone: (0702) 616333 (24 lines).

For Constipation

Fybogel Orange—gentle but effective
Fybogel Orange treats constipation gently but effectively by increasing bulk in the colon and thus encouraging normal, healthy peristalsis with soft, formed stools.[1]

Fybogel Orange—rapid first-line therapy
In a recent study of 224 newly presenting constipation patients treated with Fybogel Orange, 63.1% had a motion within 24 hours—and after 48 hours of Fybogel Orange 89.9% of patients had achieved bowel movement.[2]

Fybogel Orange—the patients' first choice for flavour
Recent tasting research showed that patients prefer orange flavoured bulking agents.[3]

Fybogel Orange

Ispaghula husk BP

gently does it

Active ingredients: Each sachet contains 3.5g Ispaghula husk BP. **Indications:** Conditions requiring a high-fibre regimen. **Dosage and Administration:** (To be taken in water.) Adults and children over 12: One sachet morning and evening. Children under 12: One half to one level 5ml spoonful depending on age and size, morning and evening. **Contra-indications, Warnings, etc.:** Fybogel is contra-indicated in cases of intestinal obstruction and colonic atony. **Basic NHS Price:** At April '88 60 sachets £4.24, Eire: 60 sachets IR £4.92. **PL No.:** Fybogel Orange 44/0068, Fybogel 44/0041. **Irish P.A. No.:** Fybogel Orange 27/2/2, Fybogel 27/2/1. **References:** 1. Data on file, 1985, Reckitt & Colman Pharmaceutical Division. 2. Data on file, 1988, Reckitt & Colman Pharmaceutical Division. 3. Data on file, 1987, Reckitt & Colman Pharmaceutical Division. Fybogel is a trade mark. Further information is available from Reckitt & Colman Pharmaceutical Division, Dansom Lane, Hull HU8 7DS.

Rapid relief for patients gripped by IBS

Colofac rapidly relieves the symptoms of Irritable Bowel Syndrome by a direct action on colonic smooth muscle.

Colofac eliminates spasm without the anti-cholinergic side effects that can prove troublesome to the patient.

colofac®

mebeverine

loosens the grip of IBS

Prescribing Information
Presentation: White, sugar-coated tablets each containing 135mg mebeverine hydrochloride. Available in packs of 100. Basic NHS price £8.35. Yellow, banana-flavoured sugar-free suspension containing mebeverine pamoate equivalent to 50mg mebeverine hydrochloride per 5ml. Available in bottles of 300ml: Basic NHS price £3.50. **Indications:** 1. Irritable bowel syndrome. 2. Gastrointestinal spasm secondary to organic diseases. **Dosage and Administration:** Tablets: Adults and children ten years and over: One tablet three times a day, preferably 20 minutes before meals. Suspension: Adults and children ten years and over: 15ml (150mg) three times a day, preferably 20 minutes before meals. **Contra-indications, warnings, etc:** Animal experiments have failed to show any teratogenic effects. However, the usual precautions concerning the administration of any drug during pregnancy should be observed. **Product Licence Number:** *Tablets:* 0512/0044: *Suspension:* 0512/0061. Further information is available on request to the Company.

duphar Duphar Laboratories Limited, Gaters Hill, West End, Southampton, SO3 3JD. Telephone: 0703 472281

C/Hosp Ad/1/88

STRENGTH AGAINST REFLUX[1]



In the management of reflux oesophagitis and hiatus hernia the role of Liquid Gaviscon is well established. Liquid Gaviscon deals with reflux simply and physically by forming a neutral layer or 'raft' on gastric contents to inhibit reflux and so bring effective relief of reflux-related upper gastro-intestinal symptoms.

More recently an in-vitro comparison[1] using computer-based techniques, has shown that Liquid Gaviscon produces a 'raft' more resistant to upward pressures than any other alginate-containing compound tested.

Liquid Gaviscon®

Sodium Alginate BPC, Sodium Bicarbonate Ph.Eur., Calcium Carbonate Ph.Eur.

a logical choice in reflux

Prescribing Information
Active Ingredients: Sodium Alginate BPC 500mg, Sodium Bicarbonate Ph.Eur. 267mg per 10ml; Calcium Carbonate 160mg per 10ml dose. **Indications:** Heartburn, including heartburn of pregnancy, dyspepsia associated with gastric reflux, hiatus hernia and reflux oesophagitis. **Contra-indications:** None known. **Dosage and Administration:** Adults, children over 12: 10-20ml liquid after meals and at bedtime. Infants: not recommended. Children under 12: 5-10ml liquid after meals and at bedtime. **Note:** 10ml liquid contains 6.2mmol sodium. **Basic NHS Cost:** As at Jan. 1988: 500ml liquid £2.88, Irish Price IR £3.72. **PL:** 44/0058. **Irish P.A. No.:** 27/12/1.

Reference
1. Washington, N. *et al., Int. J. Pharmaceut.* (1986) **28,** 139-143

Further information is available on request.
Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS.
®Registered trade mark.

WHEN LIFE'S A PAIN



PRESCRIBING INFORMATION
Presentation: Enteric-coated hard gelatin capsule. Each contains 0.2 ml standardised peppermint oil B.P, Ph. Eur. **Uses:** For the treatment of symptoms of discomfort and of abdominal colic and distension experienced by patients with Irritable Bowel Syndrome. **Dosage and Administration:** One capsule three times a day, preferably before meals and taken with a small quantity of water. The capsules should not be taken immediately after food. The dose may be increased to two capsules, three times a day when discomfort is more severe. The capsules should be taken until symptoms resolve, usually within one or two weeks. At times when symptoms are more persistent, the capsules can be continued for longer periods of between 2 to 3 months. There is no experience in the use of these capsules in children under the age of 15 years. **Contra indications, Precautions, Warnings, etc.:** The capsules should not be broken or chewed. Patients who already suffer from heartburn, sometimes experience an exacerbation of these symptoms when taking the capsule. Treatment should be discontinued in these patients. **Adverse effects:** Heartburn, sensitivity reactions to menthol which are rare, and include erythematous skin rash, headache, bradycardia, muscle tremor and ataxia. **Product Licence** PL 0424/0009. **Basic NHS Cost:** £12.15 per 100. UK and Foreign Patents pending. Colpermin is a trade mark of Tillotts Laboratories. Further information is available from Tillotts Laboratories, Valley Road Industrial Estate, Porters Wood, St Albans, Herts AL3 6PD.
European Patent No. 0015334 **UK Patent No.** 2006011.

IRRITABLE BOWEL SYNDROME

COLPERMIN™

(enteric-coated peppermint oil) CAPSULES

A NATURAL CHOICE

Tillotts LABORATORIES

Tillotts Laboratories Ltd., Valley Road Industrial Estate, Porters Wood, St Albans, Herts AL3 6PD.

COL/A3

A new cornerstone in the management of ulcerative colitis

- PENTASA enema – effective and well tolerated with no side effects reported in this study.[1,4]
- PENTASA enema – formulation keeps more active substance in contact with affected mucosa for a prolonged period.[2]
- PENTASA enema – resulted in significantly greater frequency of remission of clinical symptoms during the first 2 weeks (cf. prednisolone enemas).[3]
- PENTASA enema – can be safely administered to patients who are sensitised to the sulphapyridine moiety of sulphasalazine.[4]
- PENTASA enema – at least as effective as hydrocortisone and well tolerated.[5]

References: 1. Powell-Tuck J et al, Br Med J, 1986: 292: 599-602. 2. Bondeson S et al, Scand J Gastroenterol, 1984: 19: 677-682. 3. Danish ASA Group, Dig Dis & Sci, 1987: 32: 598-602. 4. Willoughby CP et al, Ital J Gastroenterol, 1986: 18: 15-17. 5. Bianchi-Porro G et al, Paper presented at British Society of Gastroenterology Meeting 14-16 Sept 1988.

PENTASA Mesalazine Enema ▼

Abridged prescribing information: Presentation: Unit dose plastic enema bottles containing 1 g Mesalazine in 100 ml suspension. **Uses:** Treatment of ulcerative colitis affecting the distal colon and rectum. **Dosage and Administration:** Adults: The recommended dosage is one enema at bedtime. Children: Not recommended. **Contraindications: Known sensitivity to salicylates. Precautions, Warnings, etc:** PENTASA is not recommended in patients with renal impairment. Patients with raised blood urea or proteinuria should be treated with caution. PENTASA should be used with caution during pregnancy and lactation. **Adverse reactions:** Adverse reactions including nausea, headache and abdominal pain may occur in a small proportion of patients. Mesalazine may be associated with the exacerbation of the symptoms of colitis in patients who have previously had this problem with sulphasalazine. **Legal Category:** POM. **Package Quantity:** Cartons containing seven individually foil-wrapped 100 ml enemas. **Basic NHS price:** £19.45 per carton. **Product Licence:** PL 3194/0027.

Full prescribing information is available on request:

NORDIC PHARMACEUTICALS LTD.,
11 Mount Rd, Feltham, Middlesex TW13 6JG. Tel: 01-898 8396.

SCANDINAVIAN JOURNAL OF Gastroenterology

VOLUME 24, NO. 2, MARCH 1989

CONTENTS

Abstracted in *Excerpta Medica*
Indexed in *Current Contents* and *Index Medicus* ISSN 0036–5521
Spanish edition distributed by Sanidad Ediciones, S.A.
Chinese edition distributed by The Shanghai Institute of Digestive Diseases

Annual subscription (ten issues per year) USD 364.00

Publisher: Norwegian University Press (Universitetsforlaget/AS), P.O. Box 2959 Tøyen, Oslo 6, Norway.
U.S. office: Publications Expediting Inc., 200 Meacham Ave., Elmont, NY 11003, USA